When markets soar, fear sets in. But ditching a regular investing strategy at the top could sabotage long-term success.

Elston’s Bruce Williams discuss ResMed's results and margin momentum, and whether the stock still deserves a buy rating.

Reporting season is stressful, but it also serves as a reminder of the importance of stepping back to reflect on broader themes shaping the world around us. One topic increasingly dominating ...

It is normal to feel nervous about investing when the stock market is at an all-time high, but history suggests that giving ...

Not sure where to start this ASX FY25 reporting season? NAOS analyses keywords in earnings call transcripts to reveal the ...

Austal now has 12 US defence programs — but it all began with a $200K startup. Here’s how John Rothwell got it there.

At the smaller end of the market, where companies are less closely followed and analysed, it can often take significant ...

Wilson AM’s Damien Boey explains how the WAM Income Maximiser blends equity and debt to deliver flexible, inflation-aware ...

Stock price swings on earnings day have nearly doubled in 20 years as markets price information instantly, eliminating gradual adjustments.

One question I get asked often is how US equities can keep rising even as the US dollar weakens. At face value, it feels ...

Trump’s tariff backdown hit the price but supply-demand themes remain strong; Sunstone among potential targets; ETM's Spanish acquisition.